UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Cancer pain management: Interventional therapies

Authors
Russell K Portenoy, MD
David J Copenhaver, MD
Section Editors
Janet Abrahm, MD
Scott Fishman, MD
Deputy Editors
Diane MF Savarese, MD
Marianna Crowley, MD

INTRODUCTION

A substantial number of patients with cancer pain do not obtain satisfactory relief with conventional first-line approaches, including treatment of underlying causes, if possible, opioid-based pharmacotherapy, and noninvasive second-line therapies. For some of these patients, the so called “interventional” pain management strategies may offer safe and effective pain relief. The term “interventional” usually is applied to a group of invasive analgesic therapies, including injection-based treatments, catheter-based infusion therapies, implanted devices, and some surgical approaches.

In the present era, most interventional strategies are nondestructive and are performed using needles (table 1). Some are neurolytic, however, and some involve sophisticated technology, such as implanted neurostimulation and neuraxial drug infusion devices. The evidence base for all of these approaches is limited, particularly in the population with cancer pain, and there are very few controlled trials. Nevertheless, experience in the management of acute and chronic pain suggests that a carefully selected subset of patients with cancer pain may benefit from these procedures.

With the exception of some simple injections (eg, trigger point injections), interventional therapies for pain management are implemented by professionals who have received specialized training. All clinicians involved in the management of cancer pain should have an appreciation for the indications, risks, and benefits associated with the various interventional approaches. If pharmacotherapy is unsuccessful or the benefits versus risks of an intervention outweigh those of other options including pharmacotherapy, an interventional procedure may be a viable alternative, and the patient should have access to a specialist who can confirm the appropriateness of interventional treatments and safely implement them as needed.

This topic will discuss interventional therapies for cancer pain. General principles of cancer pain assessment and management, the use of pharmacologic therapies for cancer pain, and psychological, rehabilitative, and integrative therapies are discussed separately. (See "Assessment of cancer pain" and "Overview of cancer pain syndromes" and "Cancer pain management with opioids: Optimizing analgesia" and "Cancer pain management: Adjuvant analgesics (coanalgesics)" and "Cancer pain management: Use of acetaminophen and nonsteroidal antiinflammatory drugs" and "Psychological, rehabilitative, and integrative therapies for cancer pain".)

INJECTION THERAPIES

Soft tissue and joint injections — Injections into soft tissue and joints are often performed in the management of common chronic non-cancer pain syndromes, such as myofascial pain or painful arthropathy. A patient with cancer who develops one of these painful conditions should be considered a candidate for the appropriate intervention, as long as they do not have a contraindication (eg, coagulopathy or leukopenia, pneumothorax), and the decision to proceed or not should be based on a careful assessment of benefits, risks, alternative treatments, and the overall goals of care. (See "Overview of cancer pain syndromes".)

                        

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2017. | This topic last updated: May 08, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Sist T, Miner M, Lema M. Characteristics of postradical neck pain syndrome: a report of 25 cases. J Pain Symptom Manage 1999; 18:95.
  2. Sist T, Wong C. Difficult problems and their solutions in patients with cancer pain of the head and neck areas. Curr Rev Pain 2000; 4:206.
  3. Health Quality Ontario. Vertebral Augmentation Involving Vertebroplasty or Kyphoplasty for Cancer-Related Vertebral Compression Fractures: A Systematic Review. Ont Health Technol Assess Ser 2016; 16:1.
  4. Chew C, Craig L, Edwards R, et al. Safety and efficacy of percutaneous vertebroplasty in malignancy: a systematic review. Clin Radiol 2011; 66:63.
  5. Bouza C, López-Cuadrado T, Cediel P, et al. Balloon kyphoplasty in malignant spinal fractures: a systematic review and meta-analysis. BMC Palliat Care 2009; 8:12.
  6. Berenson J, Pflugmacher R, Jarzem P, et al. Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol 2011; 12:225.
  7. Molloy S, Sewell MD, Platinum J, et al. Is balloon kyphoplasty safe and effective for cancer-related vertebral compression fractures with posterior vertebral body wall defects? J Surg Oncol 2016; 113:835.
  8. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017; 7:4.
  9. Chwistek M, Mehta RS. Vertebroplasty and kyphoplasty for vertebral compression fractures #202. J Palliat Med 2012; 15:1151.
  10. Hentschel SJ, Burton AW, Fourney DR, et al. Percutaneous vertebroplasty and kyphoplasty performed at a cancer center: refuting proposed contraindications. J Neurosurg Spine 2005; 2:436.
  11. Köse KC, Cebesoy O, Akan B, et al. Functional results of vertebral augmentation techniques in pathological vertebral fractures of myelomatous patients. J Natl Med Assoc 2006; 98:1654.
  12. Terpos E, Morgan G, Dimopoulos MA, et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 2013; 31:2347.
  13. Khan OA, Brinjikji W, Kallmes DF. Vertebral augmentation in patients with multiple myeloma: a pooled analysis of published case series. AJNR Am J Neuroradiol 2014; 35:207.
  14. Sabuncuoğlu H, Dinçer D, Güçlü B, et al. Intradural cement leakage: a rare complication of percutaneous vertebroplasty. Acta Neurochir (Wien) 2008; 150:811.
  15. Solberg J, Copenhaver D, Fishman SM. Medial branch nerve block and ablation as a novel approach to pain related to vertebral compression fracture. Curr Opin Anaesthesiol 2016; 29:596.
  16. Straube S, Derry S, Moore RA, McQuay HJ. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. Cochrane Database Syst Rev 2010; :CD002918.
  17. Pacenta HL, Kaddoum RN, Pereiras LA, et al. Continuous tunnelled femoral nerve block for palliative care of a patient with metastatic osteosarcoma. Anaesth Intensive Care 2010; 38:563.
  18. Fujii T, Nagaro T, Tsubota S, et al. Case reports: management of intractable upper extremity pain with continuous subarachnoid block at the low cervical level without impairment of upper extremity function. Anesth Analg 2010; 110:1721.
  19. Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast syndrome. Clin J Pain 2000; 16:327.
  20. Chambers WA. Nerve blocks in palliative care. Br J Anaesth 2008; 101:95.
  21. Burton, AW, Phan, PC, Cousins, MJ. Treatment of cancer pain: Role of neural blockade and neuromodulation. In: Cousins and Bridenbaugh's Neural Blockade in Clinical Anesthesia and Pain Medicine, 4th, Lippincott, Williams & Wilkins, 2009. p.1122.
  22. Lema, MJ. Invasive procedures for cancer pain. Pain: Clinical Updates; 6:1. International Association for the Study of Pain ( IASP) available online at http://www.iasp-pain.org/AM/AMTemplate.cfm?Section=Home&TEMPLATE=/CM/ContentDisplay.cfm&CONTENTID=7603.
  23. Rowe DS. Neurolytic techniques for pain management. Jacksonville Medicine; October 1998. http://www.dcmsonline.org/jax-medicine/1998journals/october98/neurolytic.htm (Accessed on March 28, 2011).
  24. Ganji, A. Cancer pain management. Biomedical Imaging and Intervention Journal 2007; 3(1):e12, accessed online at http://www.biij.org/2007/1/e12/abstract.asp?ID=230 (Accessed on August 30, 2010).
  25. Slatkin NE, Rhiner M. Phenol saddle blocks for intractable pain at end of life: report of four cases and literature review. Am J Hosp Palliat Care 2003; 20:62.
  26. Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007519.
  27. Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain-time effect: a prospective, randomized multicenter study. J Pain Symptom Manage 2014; 48:944.
  28. Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.
  29. Plancarte R, de Leon-Casasola OA, El-Helaly M, et al. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997; 22:562.
  30. de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain 1993; 54:145.
  31. Gronseth G, Cruccu G, Alksne J, et al. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the European Federation of Neurological Societies. Neurology 2008; 71:1183.
  32. Hong D, Andrén-Sandberg A. Punctate midline myelotomy: a minimally invasive procedure for the treatment of pain in inextirpable abdominal and pelvic cancer. J Pain Symptom Manage 2007; 33:99.
  33. Nauta HJ, Soukup VM, Fabian RH, et al. Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg 2000; 92:125.
  34. Al-Chaer ED, Lawand NB, Westlund KN, Willis WD. Visceral nociceptive input into the ventral posterolateral nucleus of the thalamus: a new function for the dorsal column pathway. J Neurophysiol 1996; 76:2661.
  35. Hirshberg RM, Al-Chaer ED, Lawand NB, et al. Is there a pathway in the posterior funiculus that signals visceral pain? Pain 1996; 67:291.
  36. Kim YS, Kwon SJ. High thoracic midline dorsal column myelotomy for severe visceral pain due to advanced stomach cancer. Neurosurgery 2000; 46:85.
  37. Nauta HJ, Hewitt E, Westlund KN, Willis WD Jr. Surgical interruption of a midline dorsal column visceral pain pathway. Case report and review of the literature. J Neurosurg 1997; 86:538.
  38. Hwang SL, Lin CL, Lieu AS, et al. Punctate midline myelotomy for intractable visceral pain caused by hepatobiliary or pancreatic cancer. J Pain Symptom Manage 2004; 27:79.
  39. Landau B, Levy RM. Neuromodulation techniques for medically refractory chronic pain. Annu Rev Med 1993; 44:279.
  40. Ferrante FM. Neuraxial infusion in the management of cancer pain. Oncology (Williston Park) 1999; 13:30.
  41. Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20:4040.
  42. Gildenberg, PL. History of electrical neuromodulation for chronic pain. Pain Medicine 2006; 7:S7. Available online at http://www.sld.cu/galerias/pdf/sitios/rehabilitacion-fis/history_of_electrical_neuromodulation_for_chronic_pain.pdf (Accessed on August 30, 2010).
  43. McCartney, CJL, Chambers, WA. Central neuraxial techniques for cancer pain. Curr Anaesth Crit Care 2000; 11:166.Available online at http://www.currentanaesthesia.com/article/S0953-7112(00)90268-0/abstract (Accessed on August 30, 2010).
  44. Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev 2015; :CD009389.
  45. Deer TR, Mekhail N, Provenzano D, et al. The appropriate use of neurostimulation of the spinal cord and peripheral nervous system for the treatment of chronic pain and ischemic diseases: the Neuromodulation Appropriateness Consensus Committee. Neuromodulation 2014; 17:515.
  46. Brogan S, Junkins S. Interventional therapies for the management of cancer pain. J Support Oncol 2010; 8:52.
  47. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference 2012: recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2012; 15:436.
  48. Birthi P, Sloan P. Interventional treatment of refractory cancer pain. Cancer J 2013; 19:390.
  49. Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy. Neuromodulation 2017; 20:133.
  50. Hassenbusch SJ, Portenoy RK. Current practices in intraspinal therapy--a survey of clinical trends and decision making. J Pain Symptom Manage 2000; 20:S4.
  51. Deer TR, Pope JE, Hayek SM, et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines. Neuromodulation 2017; 20:96.
  52. Deer TR, Pope JE, Hayek S, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines [published online January 2, 2017]. Neuromodulation. doi: 10.1111/ner.12538
  53. Brogan SE, Winter NB, Okifuji A. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med 2015; 40:369.
  54. Smith TJ, Coyne PJ, Staats PS, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). Ann Oncol 2005; 16:825.
  55. Sjöberg M, Nitescu P, Appelgren L, Curelaru I. Long-term intrathecal morphine and bupivacaine in patients with refractory cancer pain. Results from a morphine:bupivacaine dose regimen of 0.5:4.75 mg/ml. Anesthesiology 1994; 80:284.
  56. Hassenbusch SJ, Pillay PK, Magdinec M, et al. Constant infusion of morphine for intractable cancer pain using an implanted pump. J Neurosurg 1990; 73:405.
  57. Holmfred A, Vikerfors T, Berggren L, Gupta A. Intrathecal catheters with subcutaneous port systems in patients with severe cancer-related pain managed out of hospital: the risk of infection. J Pain Symptom Manage 2006; 31:568.
  58. Mercadante S, Intravaia G, Villari P, et al. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids. Clin J Pain 2007; 23:793.
  59. Deer TR, Levy R, Prager J, et al. Polyanalgesic Consensus Conference--2012: recommendations to reduce morbidity and mortality in intrathecal drug delivery in the treatment of chronic pain. Neuromodulation 2012; 15:467.
  60. Deer TR, Prager J, Levy R, et al. Polyanalgesic Consensus Conference--2012: consensus on diagnosis, detection, and treatment of catheter-tip granulomas (inflammatory masses). Neuromodulation 2012; 15:483.
  61. Dennis GC, DeWitty RL. Long-term intraventricular infusion of morphine for intractable pain in cancer of the head and neck. Neurosurgery 1990; 26:404.
  62. Karavelis A, Foroglou G, Selviaridis P, Fountzilas G. Intraventricular administration of morphine for control of intractable cancer pain in 90 patients. Neurosurgery 1996; 39:57.
  63. Raffa RB, Pergolizzi JV Jr. Intracerebroventricular opioids for intractable pain. Br J Clin Pharmacol 2012; 74:34.